Breaking News

Today
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
Merck begins tender offer to acquire Pandion Therapeutics for $60 per share » 06:49
03/04/21
03/04
06:49
03/04/21
06:49
MRK

Merck

$73.30 /

+0.46 (+0.63%)

, PAND

Pandion Therapeutics

$61.62 /

+0.56 (+0.92%)

Merck (MRK) is…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
PAND Pandion Therapeutics
$61.62 /

+0.56 (+0.92%)

MRK Merck
$73.30 /

+0.46 (+0.63%)

MRK Merck
$73.30 /

+0.46 (+0.63%)

02/25/21 SVB Leerink
Pandion Therapeutics downgraded to Market Perform from Outperform at SVB Leerink
02/25/21 Morgan Stanley
Pandion downgraded to Equal Weight from Overweight at Morgan Stanley
02/17/21 William Blair
William Blair 'highly encouraged' by Nektar's collaborations with Merk, SFJ
01/21/21 Wedbush
Scholar Rock price target raised to $66 from $47 at Wedbush
PAND Pandion Therapeutics
$61.62 /

+0.56 (+0.92%)

01/04/21 Goldman Sachs
Pandion's PT101 'well-positioned' vs. competitors, says Goldman Sachs
08/11/20
Fly Intel: Top five analyst initiations
PAND Pandion Therapeutics
$61.62 /

+0.56 (+0.92%)

MRK Merck
$73.30 /

+0.46 (+0.63%)

  • 17
    Jul
MRK Merck
$73.30 /

+0.46 (+0.63%)

PAND Pandion Therapeutics
$61.62 /

+0.56 (+0.92%)

MRK Merck
$73.30 /

+0.46 (+0.63%)

MRK Merck
$73.30 /

+0.46 (+0.63%)

Yesterday
Recommendations
Bayer price target raised to EUR 68 from EUR 60 at Berenberg » 14:38
03/03/21
03/03
14:38
03/03/21
14:38
BAYRY

Bayer

$0.00 /

+ (+0.00%)

Berenberg analyst…

Berenberg analyst Sebastian Bray raised the firm's price target on Bayer to EUR 68 from EUR 60 and keeps a Buy rating on the shares.

ShowHide Related Items >><<
BAYRY Bayer
$0.00 /

+ (+0.00%)

BAYRY Bayer
$0.00 /

+ (+0.00%)

03/02/21 Citi
Atara Biotherapeutics upgraded to Buy at Citi following 35% pullback
03/01/21 Morgan Stanley
Bayer price target lowered to EUR 66 from EUR 68 at Morgan Stanley
02/26/21 Credit Suisse
Bayer price target raised to EUR 56 from EUR 55 at Credit Suisse
02/10/21 Barclays
Bayer price target raised to EUR 55 from EUR 50 at Barclays
BAYRY Bayer
$0.00 /

+ (+0.00%)

BAYRY Bayer
$0.00 /

+ (+0.00%)

BAYRY Bayer
$0.00 /

+ (+0.00%)

Tuesday
On The Fly
Fly Intel: Wall Street's top stories for Tuesday » 16:48
03/02/21
03/02
16:48
03/02/21
16:48
TGT

Target

$173.40 /

-12.72 (-6.83%)

, KSS

Kohl's

$57.36 /

+0.41 (+0.72%)

, ZM

Zoom Video

$372.72 /

-36.95 (-9.02%)

, MRK

Merck

$72.85 /

+0.48 (+0.66%)

, JNJ

Johnson & Johnson

$159.01 /

-0.32 (-0.20%)

, ULTA

Ulta Beauty

$336.74 /

-0.84 (-0.25%)

, AAPL

Apple

$125.17 /

-2.6 (-2.03%)

, INTC

Intel

$61.22 /

-1.66 (-2.64%)

, PERI

Perion Network

$25.64 /

+4.135 (+19.23%)

, MORF

Morphic

$70.99 /

-13.82 (-16.30%)

, FGEN

FibroGen

$38.11 /

-12.15 (-24.17%)

, NVAX

Novavax

$205.89 /

-34.44 (-14.33%)

, RKT

Rocket Companies

$41.70 /

+17.4 (+71.60%)

Equity futures were…

ShowHide Related Items >><<
ZM Zoom Video
$372.72 /

-36.95 (-9.02%)

ULTA Ulta Beauty
$336.74 /

-0.84 (-0.25%)

TGT Target
$173.40 /

-12.72 (-6.83%)

RKT Rocket Companies
$41.70 /

+17.4 (+71.60%)

PERI Perion Network
$25.64 /

+4.135 (+19.23%)

NVAX Novavax
$205.89 /

-34.44 (-14.33%)

MRK Merck
$72.85 /

+0.48 (+0.66%)

MORF Morphic
$70.99 /

-13.82 (-16.30%)

KSS Kohl's
$57.36 /

+0.41 (+0.72%)

JNJ Johnson & Johnson
$159.01 /

-0.32 (-0.20%)

INTC Intel
$61.22 /

-1.66 (-2.64%)

FGEN FibroGen
$38.11 /

-12.15 (-24.17%)

AAPL Apple
$125.17 /

-2.6 (-2.03%)

TGT Target
$173.40 /

-12.72 (-6.83%)

03/03/21 Jefferies
Target price target lowered to $188 from $205 at Jefferies
03/03/21 DA Davidson
Target price target lowered to $210 from $229 at DA Davidson
03/03/21 Stifel
Stifel buyers on weakness in Target, sees pullback as attractive entry point
03/02/21 Baird
Target price target lowered to $200 from $220 at Baird
KSS Kohl's
$57.36 /

+0.41 (+0.72%)

03/03/21 Credit Suisse
Kohl's price target raised to $58 from $30 at Credit Suisse
03/03/21 Cowen
Kohl's price target raised to $67 from $65 at Cowen
03/03/21 Citi
Kohl's price target raised to $67 from $56 at Citi
02/18/21 Morgan Stanley
Kohl's price target raised to $40 from $27 at Morgan Stanley
ZM Zoom Video
$372.72 /

-36.95 (-9.02%)

03/02/21
Fly Intel: Top five analyst upgrades
03/02/21 Morgan Stanley
Zoom Video price target raised to $420 from $390 at Morgan Stanley
03/02/21 Piper Sandler
Zoom Video upgraded to Overweight from Neutral at Piper Sandler
01/26/21 MKM Partners
Fiverr downgraded to Sell from Neutral at MKM Partners
MRK Merck
$72.85 /

+0.48 (+0.66%)

02/25/21 SVB Leerink
Pandion Therapeutics downgraded to Market Perform from Outperform at SVB Leerink
02/25/21 Morgan Stanley
Pandion downgraded to Equal Weight from Overweight at Morgan Stanley
02/17/21 William Blair
William Blair 'highly encouraged' by Nektar's collaborations with Merk, SFJ
01/21/21 Wedbush
Scholar Rock price target raised to $66 from $47 at Wedbush
JNJ Johnson & Johnson
$159.01 /

-0.32 (-0.20%)

02/10/21 BTIG
Model N upgraded to Buy from Neutral at BTIG
02/01/21 SVB Leerink
Moderna price target raised to $80 from $69 at SVB Leerink
02/01/21 Wells Fargo
Moderna price target raised to $145 from $129 at Wells Fargo
02/01/21 BofA
BofA downgrades Moderna to Underperform, sees shares priced for 'best-case'
ULTA Ulta Beauty
$336.74 /

-0.84 (-0.25%)

03/01/21 UBS
Ulta Beauty price target raised to $365 from $335 at UBS
02/17/21 Oppenheimer
Ulta Beauty price target raised to $360 from $305 at Oppenheimer
01/27/21 Citi
Ulta Beauty downgraded to Neutral from Buy at Citi
01/21/21 Wells Fargo
Ulta Beauty price target raised to $330 from $320 at Wells Fargo
AAPL Apple
$125.17 /

-2.6 (-2.03%)

03/01/21 Wedbush
Asia checks bullish for Apple iPhone 12 builds, says Wedbush
03/01/21 JPMorgan
Broadcom won new new wireless charging chipset in iPhone 13, says JPMorgan
02/25/21 JPMorgan
JPMorgan 'tweaks' EPS estimate for Apple after cut to iPhone forecasts
02/24/21 Piper Sandler
Piper sees Apple developing 'full-blown' branded electric vehicle
INTC Intel
$61.22 /

-1.66 (-2.64%)

02/25/21 Mizuho
Intel price target raised to $70 from $68 at Mizuho
02/12/21 Lynx
Intel price target raised to $75 from $70 at Lynx
02/08/21 Loop Capital
MaxLinear upgraded to Buy from Hold at Loop Capital
02/01/21
Fly Intel: Top five analyst downgrades
PERI Perion Network
$25.64 /

+4.135 (+19.23%)

02/10/21 Lake Street
Perion Network price target raised to $30 from $18 at Lake Street
02/10/21 Roth Capital
Perion Network price target raised to $30 from $16 at Roth Capital
01/04/21 Lake Street
Perion Network price target raised to $18 from $12 at Lake Street
12/31/20 Sidoti
Perion Network price target raised to $14 from $12 at Sidoti
MORF Morphic
$70.99 /

-13.82 (-16.30%)

03/01/21 Wells Fargo
Morphic Holding price target raised to $103 from $40 at Wells Fargo
02/02/21 RBC Capital
Morphic Holding price target raised to $50 from $35 at RBC Capital
10/26/20 RBC Capital
Morphic Holding initiated with an Outperform at RBC Capital
08/11/20 BMO Capital
Morphic Holding price target raised to $37 from $30 at BMO Capital
FGEN FibroGen
$38.11 /

-12.15 (-24.17%)

03/02/21
Fly Intel: Top five analyst downgrades
03/02/21 Jefferies
FibroGen downgraded to Hold at Jefferies on increased risk for roxadustat
03/02/21 Citi
FibroGen selloff on FDA panel a buying opportunity, says Citi
03/02/21 Jefferies
FibroGen downgraded to Hold from Buy at Jefferies
NVAX Novavax
$205.89 /

-34.44 (-14.33%)

02/23/21 B. Riley Securities
B. Riley remains 'aggressive' buyer of Novavax after updated FDA guidance
02/22/21 Cantor Fitzgerald
Cantor says PREVENT-19 gives Novavax potential for differentiated analyses
02/22/21 B. Riley Securities
B. Riley reiterates Buy rating on Novavax as PREVENT-19 enrollment wraps up
02/18/21 B. Riley Securities
Novavax price target raised to $397 from $334 at B. Riley Securities
RKT Rocket Companies
$41.70 /

+17.4 (+71.60%)

03/03/21 Zelman
Rocket Companies downgraded to Hold from Buy at Zelman
03/02/21 RBC Capital
Rocket Companies downgraded to Sector Perform from Outperform at RBC Capital
03/02/21 Wells Fargo
Wells says Rocket Companies Q4 results 'not good enough to support' today's move
01/19/21 JPMorgan
JPMorgan double downgrades Rocket on more cautious mortgage stance
ZM Zoom Video
$372.72 /

-36.95 (-9.02%)

ULTA Ulta Beauty
$336.74 /

-0.84 (-0.25%)

TGT Target
$173.40 /

-12.72 (-6.83%)

RKT Rocket Companies
$41.70 /

+17.4 (+71.60%)

PERI Perion Network
$25.64 /

+4.135 (+19.23%)

NVAX Novavax
$205.89 /

-34.44 (-14.33%)

MRK Merck
$72.85 /

+0.48 (+0.66%)

MORF Morphic
$70.99 /

-13.82 (-16.30%)

KSS Kohl's
$57.36 /

+0.41 (+0.72%)

JNJ Johnson & Johnson
$159.01 /

-0.32 (-0.20%)

INTC Intel
$61.22 /

-1.66 (-2.64%)

FGEN FibroGen
$38.11 /

-12.15 (-24.17%)

AAPL Apple
$125.17 /

-2.6 (-2.03%)

  • 03
    Mar
  • 20
    Jan
  • 13
    Jan
  • 06
    Aug
ZM Zoom Video
$372.72 /

-36.95 (-9.02%)

ULTA Ulta Beauty
$336.74 /

-0.84 (-0.25%)

TGT Target
$173.40 /

-12.72 (-6.83%)

RKT Rocket Companies
$41.70 /

+17.4 (+71.60%)

NVAX Novavax
$205.89 /

-34.44 (-14.33%)

MRK Merck
$72.85 /

+0.48 (+0.66%)

KSS Kohl's
$57.36 /

+0.41 (+0.72%)

JNJ Johnson & Johnson
$159.01 /

-0.32 (-0.20%)

INTC Intel
$61.22 /

-1.66 (-2.64%)

AAPL Apple
$125.17 /

-2.6 (-2.03%)

ZM Zoom Video
$372.72 /

-36.95 (-9.02%)

ULTA Ulta Beauty
$336.74 /

-0.84 (-0.25%)

TGT Target
$173.40 /

-12.72 (-6.83%)

RKT Rocket Companies
$41.70 /

+17.4 (+71.60%)

PERI Perion Network
$25.64 /

+4.135 (+19.23%)

MRK Merck
$72.85 /

+0.48 (+0.66%)

MORF Morphic
$70.99 /

-13.82 (-16.30%)

KSS Kohl's
$57.36 /

+0.41 (+0.72%)

JNJ Johnson & Johnson
$159.01 /

-0.32 (-0.20%)

INTC Intel
$61.22 /

-1.66 (-2.64%)

FGEN FibroGen
$38.11 /

-12.15 (-24.17%)

AAPL Apple
$125.17 /

-2.6 (-2.03%)

ZM Zoom Video
$372.72 /

-36.95 (-9.02%)

ULTA Ulta Beauty
$336.74 /

-0.84 (-0.25%)

TGT Target
$173.40 /

-12.72 (-6.83%)

RKT Rocket Companies
$41.70 /

+17.4 (+71.60%)

NVAX Novavax
$205.89 /

-34.44 (-14.33%)

MRK Merck
$72.85 /

+0.48 (+0.66%)

KSS Kohl's
$57.36 /

+0.41 (+0.72%)

JNJ Johnson & Johnson
$159.01 /

-0.32 (-0.20%)

INTC Intel
$61.22 /

-1.66 (-2.64%)

FGEN FibroGen
$38.11 /

-12.15 (-24.17%)

AAPL Apple
$125.17 /

-2.6 (-2.03%)

Hot Stocks
Merck to help produce Johnson & Johnson COVID-19 vaccine » 16:32
03/02/21
03/02
16:32
03/02/21
16:32
MRK

Merck

$72.85 /

+0.48 (+0.66%)

, JNJ

Johnson & Johnson

$159.01 /

-0.32 (-0.20%)

Merck (MRK) announced it…

Merck (MRK) announced it has entered into multiple agreements to support efforts to expand manufacturing capacity and supply of SARS-CoV-2/COVID-19 medicines and vaccines. The Biomedical Advanced Research and Development Authority, BARDA, a division of the Office of the Assistant Secretary for Preparedness and Response, ASPR, within the U.S. Department of Health and Human Services, HHS, will provide Merck with funding of up to $268.8M to adapt and make available a number of existing manufacturing facilities for the production of SARS-CoV-2/COVID-19 vaccines and medicines. Merck has also entered into agreements with Janssen Pharmaceuticals, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, to support the manufacturing and supply of Johnson & Johnson's SARS-CoV-2/COVID-19 vaccine. Merck will use its facilities in the United States to produce drug substance, formulate and fill vials of Johnson & Johnson's vaccine. Under the terms of the BARDA agreement, Merck will adapt and make available some of the company's existing manufacturing sites to accelerate manufacturing efforts for SARS-CoV-2/COVID-19 vaccines and medicines. This funding is in addition to Merck's continued investment in its global vaccines manufacturing network as part of its planned capital investments of more than $20B from 2020 through the end of 2024.

ShowHide Related Items >><<
MRK Merck
$72.85 /

+0.48 (+0.66%)

JNJ Johnson & Johnson
$159.01 /

-0.32 (-0.20%)

MRK Merck
$72.85 /

+0.48 (+0.66%)

02/25/21 SVB Leerink
Pandion Therapeutics downgraded to Market Perform from Outperform at SVB Leerink
02/25/21 Morgan Stanley
Pandion downgraded to Equal Weight from Overweight at Morgan Stanley
02/17/21 William Blair
William Blair 'highly encouraged' by Nektar's collaborations with Merk, SFJ
01/21/21 Wedbush
Scholar Rock price target raised to $66 from $47 at Wedbush
JNJ Johnson & Johnson
$159.01 /

-0.32 (-0.20%)

02/10/21 BTIG
Model N upgraded to Buy from Neutral at BTIG
02/01/21 SVB Leerink
Moderna price target raised to $80 from $69 at SVB Leerink
02/01/21 Wells Fargo
Moderna price target raised to $145 from $129 at Wells Fargo
02/01/21 BofA
BofA downgrades Moderna to Underperform, sees shares priced for 'best-case'
MRK Merck
$72.85 /

+0.48 (+0.66%)

JNJ Johnson & Johnson
$159.01 /

-0.32 (-0.20%)

MRK Merck
$72.85 /

+0.48 (+0.66%)

JNJ Johnson & Johnson
$159.01 /

-0.32 (-0.20%)

MRK Merck
$72.85 /

+0.48 (+0.66%)

JNJ Johnson & Johnson
$159.01 /

-0.32 (-0.20%)

MRK Merck
$72.85 /

+0.48 (+0.66%)

JNJ Johnson & Johnson
$159.01 /

-0.32 (-0.20%)

On The Fly
Fly Intel: Wall Street's top stories at midday » 12:25
03/02/21
03/02
12:25
03/02/21
12:25
TGT

Target

$177.29 /

-8.83 (-4.74%)

, KSS

Kohl's

$58.35 /

+1.4 (+2.46%)

, JNJ

Johnson & Johnson

$159.38 /

+0.05 (+0.03%)

, MRK

Merck

$73.20 /

+0.83 (+1.15%)

, ZM

Zoom Video

$401.54 /

-8.125 (-1.98%)

, PERI

Perion Network

$27.00 /

+5.495 (+25.55%)

, AMRS

Amyris

$20.46 /

+4.84 (+30.99%)

, MORF

Morphic

$73.25 /

-11.56 (-13.63%)

, FGEN

FibroGen

$35.50 /

-14.76 (-29.37%)

, NVAX

Novavax

$201.33 /

-39 (-16.23%)

Equity futures were…

ShowHide Related Items >><<
ZM Zoom Video
$401.54 /

-8.125 (-1.98%)

TGT Target
$177.29 /

-8.83 (-4.74%)

PERI Perion Network
$27.00 /

+5.495 (+25.55%)

NVAX Novavax
$201.33 /

-39 (-16.23%)

MRK Merck
$73.20 /

+0.83 (+1.15%)

MORF Morphic
$73.25 /

-11.56 (-13.63%)

KSS Kohl's
$58.35 /

+1.4 (+2.46%)

JNJ Johnson & Johnson
$159.38 /

+0.05 (+0.03%)

FGEN FibroGen
$35.50 /

-14.76 (-29.37%)

AMRS Amyris
$20.46 /

+4.84 (+30.99%)

TGT Target
$177.29 /

-8.83 (-4.74%)

02/09/21 Jefferies
Dollar General well-positioned to mitigate minimum wage headwind, says Jefferies
02/08/21
Fly Intel: Top five analyst upgrades
02/08/21 Stifel
Target upgraded to Buy from Hold at Stifel
01/14/21 DA Davidson
Target price target raised to $229 from $208 at DA Davidson
KSS Kohl's
$58.35 /

+1.4 (+2.46%)

02/18/21 Morgan Stanley
Kohl's price target raised to $40 from $27 at Morgan Stanley
02/05/21 Baird
Kohl's price target raised to $58 from $48 at Baird
02/05/21 Deutsche Bank
Kohl's price target raised to $55 from $51 at Deutsche Bank
02/03/21
Fly Intel: Top five analyst upgrades
JNJ Johnson & Johnson
$159.38 /

+0.05 (+0.03%)

02/10/21 BTIG
Model N upgraded to Buy from Neutral at BTIG
02/01/21 SVB Leerink
Moderna price target raised to $80 from $69 at SVB Leerink
02/01/21 Wells Fargo
Moderna price target raised to $145 from $129 at Wells Fargo
02/01/21 BofA
BofA downgrades Moderna to Underperform, sees shares priced for 'best-case'
MRK Merck
$73.20 /

+0.83 (+1.15%)

02/25/21 SVB Leerink
Pandion Therapeutics downgraded to Market Perform from Outperform at SVB Leerink
02/25/21 Morgan Stanley
Pandion downgraded to Equal Weight from Overweight at Morgan Stanley
02/17/21 William Blair
William Blair 'highly encouraged' by Nektar's collaborations with Merk, SFJ
01/21/21 Wedbush
Scholar Rock price target raised to $66 from $47 at Wedbush
ZM Zoom Video
$401.54 /

-8.125 (-1.98%)

03/02/21
Fly Intel: Top five analyst upgrades
03/02/21 Morgan Stanley
Zoom Video price target raised to $420 from $390 at Morgan Stanley
03/02/21 Piper Sandler
Zoom Video upgraded to Overweight from Neutral at Piper Sandler
01/26/21 MKM Partners
Fiverr downgraded to Sell from Neutral at MKM Partners
PERI Perion Network
$27.00 /

+5.495 (+25.55%)

02/10/21 Lake Street
Perion Network price target raised to $30 from $18 at Lake Street
02/10/21 Roth Capital
Perion Network price target raised to $30 from $16 at Roth Capital
01/04/21 Lake Street
Perion Network price target raised to $18 from $12 at Lake Street
12/31/20 Sidoti
Perion Network price target raised to $14 from $12 at Sidoti
AMRS Amyris
$20.46 /

+4.84 (+30.99%)

02/26/21
Fly Intel: Top five analyst initiations
02/26/21 Roth Capital
Amyris initiated with a Buy at Roth Capital
01/06/21 Cowen
Amyris upgraded to Outperform with $9 price target at Cowen
01/06/21 Cowen
Amyris upgraded to Outperform from Market Perform at Cowen
MORF Morphic
$73.25 /

-11.56 (-13.63%)

03/01/21 Wells Fargo
Morphic Holding price target raised to $103 from $40 at Wells Fargo
02/02/21 RBC Capital
Morphic Holding price target raised to $50 from $35 at RBC Capital
10/26/20 RBC Capital
Morphic Holding initiated with an Outperform at RBC Capital
08/11/20 BMO Capital
Morphic Holding price target raised to $37 from $30 at BMO Capital
FGEN FibroGen
$35.50 /

-14.76 (-29.37%)

03/02/21
Fly Intel: Top five analyst downgrades
03/02/21 Jefferies
FibroGen downgraded to Hold at Jefferies on increased risk for roxadustat
03/02/21 Citi
FibroGen selloff on FDA panel a buying opportunity, says Citi
03/02/21 Jefferies
FibroGen downgraded to Hold from Buy at Jefferies
NVAX Novavax
$201.33 /

-39 (-16.23%)

02/23/21 B. Riley Securities
B. Riley remains 'aggressive' buyer of Novavax after updated FDA guidance
02/22/21 Cantor Fitzgerald
Cantor says PREVENT-19 gives Novavax potential for differentiated analyses
02/22/21 B. Riley Securities
B. Riley reiterates Buy rating on Novavax as PREVENT-19 enrollment wraps up
02/18/21 B. Riley Securities
Novavax price target raised to $397 from $334 at B. Riley Securities
ZM Zoom Video
$401.54 /

-8.125 (-1.98%)

TGT Target
$177.29 /

-8.83 (-4.74%)

PERI Perion Network
$27.00 /

+5.495 (+25.55%)

NVAX Novavax
$201.33 /

-39 (-16.23%)

MRK Merck
$73.20 /

+0.83 (+1.15%)

MORF Morphic
$73.25 /

-11.56 (-13.63%)

KSS Kohl's
$58.35 /

+1.4 (+2.46%)

JNJ Johnson & Johnson
$159.38 /

+0.05 (+0.03%)

FGEN FibroGen
$35.50 /

-14.76 (-29.37%)

AMRS Amyris
$20.46 /

+4.84 (+30.99%)

  • 03
    Mar
  • 20
    Jan
  • 13
    Jan
ZM Zoom Video
$401.54 /

-8.125 (-1.98%)

TGT Target
$177.29 /

-8.83 (-4.74%)

NVAX Novavax
$201.33 /

-39 (-16.23%)

MRK Merck
$73.20 /

+0.83 (+1.15%)

KSS Kohl's
$58.35 /

+1.4 (+2.46%)

JNJ Johnson & Johnson
$159.38 /

+0.05 (+0.03%)

ZM Zoom Video
$401.54 /

-8.125 (-1.98%)

TGT Target
$177.29 /

-8.83 (-4.74%)

PERI Perion Network
$27.00 /

+5.495 (+25.55%)

NVAX Novavax
$201.33 /

-39 (-16.23%)

MRK Merck
$73.20 /

+0.83 (+1.15%)

KSS Kohl's
$58.35 /

+1.4 (+2.46%)

JNJ Johnson & Johnson
$159.38 /

+0.05 (+0.03%)

FGEN FibroGen
$35.50 /

-14.76 (-29.37%)

AMRS Amyris
$20.46 /

+4.84 (+30.99%)

ZM Zoom Video
$401.54 /

-8.125 (-1.98%)

TGT Target
$177.29 /

-8.83 (-4.74%)

NVAX Novavax
$201.33 /

-39 (-16.23%)

MRK Merck
$73.20 /

+0.83 (+1.15%)

KSS Kohl's
$58.35 /

+1.4 (+2.46%)

JNJ Johnson & Johnson
$159.38 /

+0.05 (+0.03%)

FGEN FibroGen
$35.50 /

-14.76 (-29.37%)

AMRS Amyris
$20.46 /

+4.84 (+30.99%)

Upgrade
Atara Biotherapeutics upgraded to Buy at Citi following 35% pullback » 11:04
03/02/21
03/02
11:04
03/02/21
11:04
ATRA

Atara Biotherapeutics

$16.60 /

-0.47 (-2.75%)

, BAYRY

Bayer

$0.00 /

+ (+0.00%)

As previously reported,…

As previously reported, Citi analyst Yigal Nochomovitz upgraded Atara Biotherapeutics (ATRA) to Buy from Neutral with a $27 price target, noting that the stock has retreated by about 35% since early December when a collaboration with Bayer (BAYRY) for mesothelin CART programs ATA2271 and ATA3271 was announced. He now sees a more favorable risk/reward following the pullback, pointing to upcoming catalysts that include completing the rolling BLA submission for tab-cel in R/R EBV+ PTLD in Q3, the report of initial Phase 1 data for ATA2271 in Q4, and the communication of next steps for ATA188 in MS.

ShowHide Related Items >><<
BAYRY Bayer
$0.00 /

+ (+0.00%)

ATRA Atara Biotherapeutics
$16.60 /

-0.47 (-2.75%)

ATRA Atara Biotherapeutics
$16.60 /

-0.47 (-2.75%)

03/02/21 Citi
Atara Biotherapeutics upgraded to Buy from Neutral at Citi
01/04/21 Roth Capital
Roth keeps Buy rating on Atara Biotherapeutics after filing delay
01/04/21 Roth Capital
Roth keeps Buy rating on Atara as initiation of BLA gets 'slightly' delayed
12/09/20 Citi
Atara Biotherapeutics downgraded to Neutral from Buy at Citi
BAYRY Bayer
$0.00 /

+ (+0.00%)

03/01/21 Morgan Stanley
Bayer price target lowered to EUR 66 from EUR 68 at Morgan Stanley
02/26/21 Credit Suisse
Bayer price target raised to EUR 56 from EUR 55 at Credit Suisse
02/10/21 Barclays
Bayer price target raised to EUR 55 from EUR 50 at Barclays
02/04/21
Citi opens positive 'Catalyst Watch' on Bayer
BAYRY Bayer
$0.00 /

+ (+0.00%)

ATRA Atara Biotherapeutics
$16.60 /

-0.47 (-2.75%)

  • 09
    Dec
  • 27
    May
BAYRY Bayer
$0.00 /

+ (+0.00%)

BAYRY Bayer
$0.00 /

+ (+0.00%)

ATRA Atara Biotherapeutics
$16.60 /

-0.47 (-2.75%)

Options
Unusually active option classes on open March 2nd » 09:40
03/02/21
03/02
09:40
03/02/21
09:40
RKT

Rocket Companies

$24.30 /

+ (+0.00%)

, TGT

Target

$186.12 /

+ (+0.00%)

, TXMD

TherapeuticsMD

$1.44 /

+ (+0.00%)

, KOPN

Kopin

$9.14 /

+ (+0.00%)

, SE

Sea Limited

$248.81 /

+ (+0.00%)

, XL

XL Fleet

$14.87 /

+ (+0.00%)

, SOS

SOS Limited

$6.68 /

+ (+0.00%)

, MCD

McDonald's

$208.25 /

+ (+0.00%)

, MRK

Merck

$72.37 /

+ (+0.00%)

, BYND

Beyond Meat

$147.09 /

-0.02 (-0.01%)

Unusual total active…

Unusual total active option classes on open include: Rocket Companies (RKT), Target (TGT), TherapeuticsMD (TXMD), Kopin (KOPN), Sea Limited (SE), XL Fleet (XL), SOS Limited (SOS), McDonald's (MCD), Merck (MRK), and Beyond Meat (BYND).

ShowHide Related Items >><<
XL XL Fleet
$14.87 /

+ (+0.00%)

TXMD TherapeuticsMD
$1.44 /

+ (+0.00%)

TGT Target
$186.12 /

+ (+0.00%)

SOS SOS Limited
$6.68 /

+ (+0.00%)

SE Sea Limited
$248.81 /

+ (+0.00%)

RKT Rocket Companies
$24.30 /

+ (+0.00%)

MRK Merck
$72.37 /

+ (+0.00%)

MCD McDonald's
$208.25 /

+ (+0.00%)

KOPN Kopin
$9.14 /

+ (+0.00%)

BYND Beyond Meat
$147.09 /

-0.02 (-0.01%)

RKT Rocket Companies
$24.30 /

+ (+0.00%)

01/19/21 JPMorgan
JPMorgan double downgrades Rocket on more cautious mortgage stance
01/19/21 JPMorgan
Rocket Companies downgraded to Underweight from Overweight at JPMorgan
12/17/20 Keefe Bruyette
Rocket Companies downgraded to Underperform at Keefe Bruyette
12/14/20
Fly Intel: Top five analyst initiations
TGT Target
$186.12 /

+ (+0.00%)

02/09/21 Jefferies
Dollar General well-positioned to mitigate minimum wage headwind, says Jefferies
02/08/21
Fly Intel: Top five analyst upgrades
02/08/21 Stifel
Target upgraded to Buy from Hold at Stifel
01/14/21 DA Davidson
Target price target raised to $229 from $208 at DA Davidson
TXMD TherapeuticsMD
$1.44 /

+ (+0.00%)

01/28/21 H.C. Wainwright
TherapeuticsMD price target lowered to $4 from $5 at H.C. Wainwright
08/07/20 Jefferies
Jefferies downgrades 'show-me story' TherapeuticsMD to Underperform
08/07/20 Jefferies
TherapeuticsMD downgraded to Underperform from Hold at Jefferies
05/19/20
Fly Intel: Top five analyst downgrades
KOPN Kopin
$9.14 /

+ (+0.00%)

01/11/21 H.C. Wainwright
Kopin price target raised to $3.50 from $2 at H.C. Wainwright
08/25/20
Fly Intel: Top five analyst initiations
08/25/20 H.C. Wainwright
Kopin initiated with a Buy at H.C. Wainwright
08/05/20 Ladenburg
Kopin price target raised to $2.50 from $1.50 at Ladenburg
SE Sea Limited
$248.81 /

+ (+0.00%)

02/23/21 Cowen
Sea Limited price target raised to $320 from $225 at Cowen
02/01/21 China Renaissance
Sea Limited initiated with a Buy at China Renaissance
02/01/21 Morgan Stanley
Sea Limited price target raised to $250 from $188 at Morgan Stanley
01/08/21 Stifel
Sea Group secures banking license in Indonesia, says Stifel
XL XL Fleet
$14.87 /

+ (+0.00%)

01/29/21 Canaccord
Canaccord sees XL Fleet going to $30 per share on 'first-mover' advantage
01/29/21 Canaccord
XL Fleet initiated with a Buy at Canaccord
01/22/21
Fly Intel: Top five analyst initiations
01/22/21 BTIG
XL Fleet initiated with a Buy at BTIG
SOS SOS Limited
$6.68 /

+ (+0.00%)

MCD McDonald's
$208.25 /

+ (+0.00%)

03/02/21 Citi
Citi upgrades Beyond Meat to Buy with 'new-found enthusiasm' for long-term story
02/22/21 Wells Fargo
Wells Fargo strategist upgrades Consumer Services sector to Overweight
02/01/21 Citi
Citi opens 'Catalyst Watch' on McDonald's into chicken sandwich launch
01/21/21 UBS
UBS sees 'golden' risk reward for McDonald's
MRK Merck
$72.37 /

+ (+0.00%)

02/25/21 SVB Leerink
Pandion Therapeutics downgraded to Market Perform from Outperform at SVB Leerink
02/25/21 Morgan Stanley
Pandion downgraded to Equal Weight from Overweight at Morgan Stanley
02/17/21 William Blair
William Blair 'highly encouraged' by Nektar's collaborations with Merk, SFJ
01/21/21 Wedbush
Scholar Rock price target raised to $66 from $47 at Wedbush
BYND Beyond Meat
$147.09 /

-0.02 (-0.01%)

03/02/21 Citi
Beyond Meat upgraded to Buy from Neutral at Citi
03/01/21 DA Davidson
Beyond Meat price target raised to $145 from $133 at DA Davidson
02/26/21 Piper Sandler
Beyond Meat relationship with McDonald's not much changed, says Piper Sandler
TXMD TherapeuticsMD
$1.44 /

+ (+0.00%)

TGT Target
$186.12 /

+ (+0.00%)

SOS SOS Limited
$6.68 /

+ (+0.00%)

SE Sea Limited
$248.81 /

+ (+0.00%)

RKT Rocket Companies
$24.30 /

+ (+0.00%)

MRK Merck
$72.37 /

+ (+0.00%)

MCD McDonald's
$208.25 /

+ (+0.00%)

KOPN Kopin
$9.14 /

+ (+0.00%)

BYND Beyond Meat
$147.09 /

-0.02 (-0.01%)

  • 11
    Feb
  • 11
    Dec
  • 10
    Nov
  • 06
    Aug
XL XL Fleet
$14.87 /

+ (+0.00%)

TGT Target
$186.12 /

+ (+0.00%)

SE Sea Limited
$248.81 /

+ (+0.00%)

RKT Rocket Companies
$24.30 /

+ (+0.00%)

MRK Merck
$72.37 /

+ (+0.00%)

MCD McDonald's
$208.25 /

+ (+0.00%)

BYND Beyond Meat
$147.09 /

-0.02 (-0.01%)

TXMD TherapeuticsMD
$1.44 /

+ (+0.00%)

TGT Target
$186.12 /

+ (+0.00%)

SE Sea Limited
$248.81 /

+ (+0.00%)

RKT Rocket Companies
$24.30 /

+ (+0.00%)

MRK Merck
$72.37 /

+ (+0.00%)

MCD McDonald's
$208.25 /

+ (+0.00%)

BYND Beyond Meat
$147.09 /

-0.02 (-0.01%)

XL XL Fleet
$14.87 /

+ (+0.00%)

TXMD TherapeuticsMD
$1.44 /

+ (+0.00%)

TGT Target
$186.12 /

+ (+0.00%)

SOS SOS Limited
$6.68 /

+ (+0.00%)

SE Sea Limited
$248.81 /

+ (+0.00%)

RKT Rocket Companies
$24.30 /

+ (+0.00%)

MRK Merck
$72.37 /

+ (+0.00%)

MCD McDonald's
$208.25 /

+ (+0.00%)

BYND Beyond Meat
$147.09 /

-0.02 (-0.01%)

Periodicals
Merck to help produce J&J Covid vaccine, Washington Post reports » 08:03
03/02/21
03/02
08:03
03/02/21
08:03
MRK

Merck

$72.37 /

-0.28 (-0.39%)

, JNJ

Johnson & Johnson

$159.34 /

+0.92 (+0.58%)

President Biden will…

President Biden will announce today that Merck (MRK) will help make Johnson & Johnson's (JNJ) single-shot coronavirus vaccine, Laurie McGinley and Christopher Rowland of Washington Post report, citing senior administration officials. Under the arrangement, Merck will dedicate two facilities in the United States to Johnson & Johnson's shots, officials told the paper. Reference Link

ShowHide Related Items >><<
MRK Merck
$72.37 /

-0.28 (-0.39%)

JNJ Johnson & Johnson
$159.34 /

+0.92 (+0.58%)

MRK Merck
$72.37 /

-0.28 (-0.39%)

02/25/21 SVB Leerink
Pandion Therapeutics downgraded to Market Perform from Outperform at SVB Leerink
02/25/21 Morgan Stanley
Pandion downgraded to Equal Weight from Overweight at Morgan Stanley
02/17/21 William Blair
William Blair 'highly encouraged' by Nektar's collaborations with Merk, SFJ
01/21/21 Wedbush
Scholar Rock price target raised to $66 from $47 at Wedbush
JNJ Johnson & Johnson
$159.34 /

+0.92 (+0.58%)

02/10/21 BTIG
Model N upgraded to Buy from Neutral at BTIG
02/01/21 SVB Leerink
Moderna price target raised to $80 from $69 at SVB Leerink
02/01/21 Wells Fargo
Moderna price target raised to $145 from $129 at Wells Fargo
02/01/21 BofA
BofA downgrades Moderna to Underperform, sees shares priced for 'best-case'
MRK Merck
$72.37 /

-0.28 (-0.39%)

JNJ Johnson & Johnson
$159.34 /

+0.92 (+0.58%)

MRK Merck
$72.37 /

-0.28 (-0.39%)

JNJ Johnson & Johnson
$159.34 /

+0.92 (+0.58%)

MRK Merck
$72.37 /

-0.28 (-0.39%)

JNJ Johnson & Johnson
$159.34 /

+0.92 (+0.58%)

MRK Merck
$72.37 /

-0.28 (-0.39%)

JNJ Johnson & Johnson
$159.34 /

+0.92 (+0.58%)

Monday
Hot Stocks
Merck announces voluntary withdrawal for KEYTRUDA in SCLC » 16:15
03/01/21
03/01
16:15
03/01/21
16:15
MRK

Merck

$72.37 /

-0.28 (-0.39%)

The company states: Merck…

The company states: Merck announced the company is voluntarily withdrawing the U.S. indication for KEYTRUDA (pembrolizumab) for the treatment of patients with metastatic small cell lung cancer with disease progression on or after platinum-based chemotherapy and at least one other prior line of therapy. The withdrawal of this indication was done in consultation with the U.S. Food and Drug Administration, and Merck is working to complete this process over the coming weeks. This decision does not affect other indications for KEYTRUDA, Merck's anti-PD-1 therapy. This accelerated approval for KEYTRUDA was granted in June 2019 based on tumor response rate and durability of response data from KEYNOTE-158 and KEYNOTE-028. Continued approval for this indication was contingent upon completion of the post-marketing requirement establishing superiority of KEYTRUDA as determined by overall survival. As announced in Jan. 2020, KEYNOTE-604, the confirmatory Phase 3 trial for this indication, met one of its dual primary endpoints of progression-free survival but did not reach statistical significance for the other primary endpoint of OS. Merck's consultation with the FDA on this withdrawal is part of an industry-wide evaluation of indications based on accelerated approvals that have not yet met their post-marketing requirements. Merck is notifying health care professionals about this withdrawal. Patients being treated with KEYTRUDA for their metastatic SCLC should discuss their care with their health care provider."

ShowHide Related Items >><<
MRK Merck
$72.37 /

-0.28 (-0.39%)

MRK Merck
$72.37 /

-0.28 (-0.39%)

02/25/21 SVB Leerink
Pandion Therapeutics downgraded to Market Perform from Outperform at SVB Leerink
02/25/21 Morgan Stanley
Pandion downgraded to Equal Weight from Overweight at Morgan Stanley
02/17/21 William Blair
William Blair 'highly encouraged' by Nektar's collaborations with Merk, SFJ
01/21/21 Wedbush
Scholar Rock price target raised to $66 from $47 at Wedbush
MRK Merck
$72.37 /

-0.28 (-0.39%)

MRK Merck
$72.37 /

-0.28 (-0.39%)

MRK Merck
$72.37 /

-0.28 (-0.39%)

MRK Merck
$72.37 /

-0.28 (-0.39%)

Recommendations
Bayer price target lowered to EUR 66 from EUR 68 at Morgan Stanley » 15:19
03/01/21
03/01
15:19
03/01/21
15:19
BAYRY

Bayer

$0.00 /

+ (+0.00%)

Morgan Stanley analyst…

Morgan Stanley analyst James Quigley lowered the firm's price target on Bayer to EUR 66 from EUR 68 and keeps an Overweight rating on the shares.

ShowHide Related Items >><<
BAYRY Bayer
$0.00 /

+ (+0.00%)

BAYRY Bayer
$0.00 /

+ (+0.00%)

02/26/21 Credit Suisse
Bayer price target raised to EUR 56 from EUR 55 at Credit Suisse
02/10/21 Barclays
Bayer price target raised to EUR 55 from EUR 50 at Barclays
02/04/21
Citi opens positive 'Catalyst Watch' on Bayer
01/27/21 Deutsche Bank
Bayer price target raised to EUR 63 from EUR 62 at Deutsche Bank
BAYRY Bayer
$0.00 /

+ (+0.00%)

BAYRY Bayer
$0.00 /

+ (+0.00%)

BAYRY Bayer
$0.00 /

+ (+0.00%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.